Tyrosine kinase inhibitorFDA-approvedFirst-line
Squibb's Tarceva
Generic name: erlotinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, around 50% of EGFR-mutated patients achieved an objective response, with median progression-free survival of approximately 13.8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Delivery System for Lung Cancer Treatment | Lung Cancer | lab-study | The maximal entrapment efficiencies for niclosamide and erlotinib were 77.97% ± 2.25% and 72.75% ± 1.49%, respectively. | Source → |
| Erlotinib Efficacy Enhanced in Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | CR:OSI-774 complexes demonstrated significantly lower IC and IC values compared to erlotinib monotherapy, indicating enhanced anti-proliferative effects. | Source → |
| Herbal Compound Sensitizes Lung Cancer Cells to Treatment | Lung Cancer | lab-study | — | Source → |
| Erlotinib Resistance in Lung Cancer: New Insights | Lung Cancer | lab-study | — | Source → |
| Zebrafish Study Identifies Erlotinib as Potential Wnt Inhibitor for Leukemia | Leukemia | lab-study | Erlotinib treatment reduced self-renewal in human T-cell Acute Lymphoblastic Leukemia cells. | Source → |
| Homoharringtonine Enhances Effectiveness of Erlotinib in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Comparing Cancer Treatments in East Asian Patients | Lung Cancer | meta-analysis | Afatinib resulted in significantly longer progression-free survival (PFS) than erlotinib (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.46-0.75) and gefitinib (HR: 0.41, 95% CI: 0.32-0.53) in patients with the EGFR L858R mutation. | Source → |
| Erlotinib Compared to Chemotherapy in Lung Cancer Treatment | Lung Cancer | phase-2 | The median overall survival was 42.2 months with erlotinib and 36.9 months with chemotherapy. | Source → |
| Erlotinib Improves Survival in Lung Cancer Patients | Lung Cancer | phase-2 | The median overall survival was 84.2 months with erlotinib versus 61.1 months with chemotherapy. | Source → |
| Proton Pump Inhibitors May Affect Lung Cancer Treatment | Lung Cancer | observational | The adjusted hazard ratio for overall survival in the PPI group was 1.58 (95% CI 1.42-1.76) compared to the non-user group. | Source → |
| Erlova Shows Promise in Treating EGFR-Mutated Lung Cancer | Lung Cancer | phase-2 | The objective response rate was about 88%. | Source → |
| New Liposomal Formulation for Targeted Cancer Treatment | Pancreatic Cancer | lab-study | The IC50 for free erlotinib and formulation was found to be 2.0 ± 0.3 µg/ml and 1.1 ± 0.1 µg/ml, respectively. | Source → |
| New Tablet Formulation May Improve Erlotinib Absorption | Lung Cancer | lab-study | — | Source → |
| Kaempferol Enhances Effectiveness of Cancer Treatment in Lab Experiments | Pancreatic Cancer | lab-study | — | Source → |
| Combining Medications May Help Prevent Intestinal Cancer | Colorectal Cancer | animal-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.